Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Vitamin Shoppe Inc (VSI), GNC Holdings Inc (GNC): Supplement Struggles

Page 1 of 2

Shareholders of the Vitamin Shoppe Inc (NYSE:VSI) are no doubt scratching there heads after the company’s terrible performance so far this year. Shares are down almost 25%, while broader markets have returned double digits on the back of economic strength and loose monetary policies. I stumbled upon this small-cap company while actually purchasing pre-workout from one of the local locations on the recommendation from a friend. Previously, I had never visited any locations nor researched the company whatsoever. I was perplexed by its terrible performance and I wanted to get to the bottom of this stock. In this article, I will share my findings and offer my take on the struggles which lay ahead.

Vitamin Shoppe Inc (NYSE:VSI)

The supplement industry is expected to grow a whopping 35% in the United States to a $15.5 billion dollar industry by 2017. The supplement industry is pretty broad, as it includes everything from multi-vitamins, weight control products, weight loss products, protein powders, fish oils, pre-workouts, mass gainers, energy bars, etc. I also took a look at competitor GNC Holdings Inc (NYSE:GNC), which is up a bulky 35% this year alone. What could be causing the huge difference in returns?

Lets first take a look at Vitamin Shoppe Inc (NYSE:VSI)

Last month, the company reported its first quarter results wherein the company announced  comparable store sales grew 4.5%, while E-commerce revenues increased 16.1%.  The company enjoyed its 7th consecutive quarter of double-digit growth, completed the acquisition of Super Supplements, earned $0.72 per share excluding transaction and integration costs from the Super Supplements acquisition, and opened 13 new stores in the U.S, alongside a South American expansion. There are obviously many positives on the surface, but when you dig deeper you see fears of a slowdown and threats of competitors on the horizon.

With the acquisition of Super Supplements, the company added 31 new locations to drive revenue growth. Unfortunately, these Super Supplement locations operate at lower margins than the company brand. When you have a perfectly competitive product in a monopolistically competitive market, economies of scale are everything. Over time, I expect Super Supplement margins to increase with the leverage of Vitamin Shoppe as its distribution channels improve. I would recommend the company completely scrap the Super Supplement identity and convert these locations into Vitamin Shoppe Inc (NYSE:VSI) stores to improve brand recognition and to drive traffic to its E-Commerce website.

When one analyst asked about unexpected weakness during the quarter, the company responded by attributing this weakness to broad economic weakness. This is a classic case of management spitting nonsense. Consumer confidence and consumer spending have been driving an economic recovery this year, as seen in the earnings of many consumer staples. This weakness needs to be attributed to weakening market share and a growing number of direct competitors. Vitamin Shoppe Inc (NYSE:VSI)’s e-commerce division has been growing strong, but this growth will not last forever. Online you can get almost every one of their products via hundreds of supplement websites. This problem is caused by the lack of differentiation between supplements. The supplements are so similar that manufacturers can not afford to limit the merchants of their products without risking losing market share of their own. As a result of this competition, margins will continue to weaken and market share will dwindle.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!